FDA Declares Tirzepatide Shortage Resolved, Tightening Rules on Compounded Copies
Tuesday, June 16th, 2026 - The U.S. Food and Drug Administration announced Monday that the nationwide shortage of tirzepatide injection, a dual GIP/GLP-1 drug sold under brand names Mounjaro and Zepbound, has been resolved, a decision that immediately restricts the ability of compounding pharmacies to produce unapproved versions of the medication. The agency's determination, published in a CDER update, ends a shortage designation that had been in place since 2022, when demand for the diabetes and weight-loss drug began outstripping supply.
Compounding pharmacies face a narrower path
With the shortage officially over, compounding pharmacies operating under section 503A of the Federal Food, Drug, and Cosmetic Act can no longer produce tirzepatide copies in bulk, and outsourcing facilities under section 503B face stricter limits. The FDA's compounding inspections, recalls, and other actions page lists ongoing enforcement priorities. The Alliance for Pharmacy Compounding, a trade group, has not yet issued a public statement on the change, according to its news feed. The Outsourcing Facilities Association, which represents 503B facilities, maintains a drug shortages page that previously listed tirzepatide as in shortage.
Warning letters remain a regulatory tool
The FDA continues to issue warning letters to compounders and other firms making unapproved claims about peptide products. The agency's warning letter page lists recent actions, though no new tirzepatide-specific letters were posted as of Tuesday. The National Association of Boards of Pharmacy, which tracks state-level pharmacy enforcement, maintains a newsroom with updates on compounding oversight.
Pipeline records keep retatrutide in focus
Clinical trial registries show continued enrollment in studies of retatrutide, an investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors. A search of ClinicalTrials.gov shows multiple ongoing Phase 2 and Phase 3 trials for the Eli Lilly asset. Company announcements from Eli Lilly and Novo Nordisk indicate both firms are advancing next-generation incretin therapies. Peer-reviewed literature in JAMA and the New England Journal of Medicine continues to publish clinical data on these agents.
Sports rules remain separate
Athletes and sports organizations should verify current anti-doping rules regarding peptide hormones. The World Anti-Doping Agency's prohibited list includes peptide hormones, growth factors, and related substances. The list is updated annually, and athletes should consult their national anti-doping organizations for the most current restrictions.
